Last checked at 6 Sep 2018 07:15
Hardman & Co Research Hardman & Co Research: Redx Pharma (REDX): Back to the clinic 06-Sep-2018 / 07:15 GMT/BST Hardman & Co: Back to the clinic Redx Pharma's (REDX) new management team is continuing to focus its financial resources on progressing its lead candidates in oncology and fibrotic disease into the clinic. When the first patient was treated with RXC004, its porcupine inhibitor, in a Phase I/IIa proof-of-concept trial, some on-target adverse events (anticipated at higher doses) were observed, management took the prudent decision to halt patient recruitment. Based on a draft modified protocol using significantly lower doses, Redx has received positive feedback from the MHRA. Redx is currently preparing the final protocol with the aim of re-starting the clinical study in 1H'19. Please click here for the full report: http://hardmanandco.com/docs/default-source/company-docs/redx-pharma--documents/06.09.18-back-to-the-clinic.pdf
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement. |
721033 06-Sep-2018
corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.